Collegium Pharmaceutical Inc., a Canton, Mass.-based company using its manufacturing platform Deterx to create an abuse-deterrent, extended-release, oral formulation of oxycodone now under review at the FDA, has filed to raise up to $86.3 million in an IPO. The company has yet to set terms for the offering.